Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ENOVNASDAQ:LIVNNASDAQ:LMATNASDAQ:SIBN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENOVEnovis$31.91+2.4%$37.53$29.32▼$56.89$1.82B1.86741,338 shs704,815 shsLIVNLivaNova$35.58+1.5%$40.08$32.48▼$64.48$1.93B0.9627,229 shs614,570 shsLMATLeMaitre Vascular$86.28+1.9%$87.85$62.39▼$109.58$1.95B0.89160,817 shs184,020 shsSIBNSI-BONE$13.85+3.9%$15.27$11.70▼$19.16$587.97M1.02364,033 shs397,377 shs7 Top Nuclear Stocks To Buy NowNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENOVEnovis+2.57%-0.26%-18.15%-31.64%-43.26%LIVNLivaNova+1.45%+4.22%-11.95%-26.34%-31.41%LMATLeMaitre Vascular+1.90%+6.05%+1.61%-12.90%+36.87%SIBNSI-BONE+3.90%+4.53%-6.36%-17.02%-9.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENOVEnovis2.4301 of 5 stars3.41.00.00.02.11.71.9LIVNLivaNova3.5663 of 5 stars4.43.00.00.02.91.71.3LMATLeMaitre Vascular3.1246 of 5 stars2.31.03.30.04.23.31.3SIBNSI-BONE4.164 of 5 stars3.54.00.03.32.72.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENOVEnovis 2.75Moderate Buy$58.5083.32% UpsideLIVNLivaNova 2.88Moderate Buy$61.1771.91% UpsideLMATLeMaitre Vascular 2.67Moderate Buy$95.2510.40% UpsideSIBNSI-BONE 3.00Buy$24.4076.17% UpsideCurrent Analyst Ratings BreakdownLatest SIBN, LIVN, LMAT, and ENOV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.00 ➝ $64.004/2/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.00 ➝ $64.003/17/2025LIVNLivaNovaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.00 ➝ $64.003/7/2025LIVNLivaNovaBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$58.00 ➝ $56.003/3/2025LIVNLivaNovaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $55.002/28/2025LMATLeMaitre VascularLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$105.00 ➝ $110.002/28/2025LMATLeMaitre VascularOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/28/2025LMATLeMaitre VascularBarrington ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/27/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$65.00 ➝ $64.002/26/2025LIVNLivaNovaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$70.00 ➝ $60.002/26/2025LIVNLivaNovaStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$72.00 ➝ $60.00(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENOVEnovis$2.11B0.86$4.65 per share6.86$62.66 per share0.51LIVNLivaNova$1.25B1.54$3.19 per share11.15$23.72 per share1.50LMATLeMaitre Vascular$219.86M8.85$1.53 per share56.52$13.38 per share6.45SIBNSI-BONE$167.18M3.52N/AN/A$4.18 per share3.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENOVEnovis-$33.26M-$14.29N/A10.00N/A-5.95%4.39%2.80%5/8/2025 (Estimated)LIVNLivaNova$17.55M$1.1484.7111.33N/A1.91%13.81%7.07%4/29/2025 (Estimated)LMATLeMaitre Vascular$30.10M$1.9447.1539.762.2219.40%13.15%11.47%5/1/2025 (Estimated)SIBNSI-BONE-$43.34M-$0.76N/AN/AN/A-23.82%-22.51%-16.53%5/5/2025 (Estimated)Latest SIBN, LIVN, LMAT, and ENOV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ENOVEnovis$0.74N/AN/AN/A$558.80 millionN/A5/7/2025Q1 2025LIVNLivaNova$0.75N/AN/AN/A$302.34 millionN/A5/5/2025Q1 2025SIBNSI-BONE-$0.24N/AN/AN/A$45.13 millionN/A5/1/2025Q1 2025LMATLeMaitre Vascular$0.50N/AN/AN/A$57.61 millionN/A2/27/2025Q4 2024LMATLeMaitre Vascular$0.49$0.49N/A$0.49$55.99 million$55.81 million2/26/2025Q4 2024ENOVEnovis$0.92$0.98+$0.06-$12.05$555.14 million$560.98 million2/24/2025Q4 2024SIBNSI-BONE-$0.16-$0.11+$0.05-$0.11$48.87 million$49.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENOVEnovisN/AN/AN/AN/AN/ALIVNLivaNovaN/AN/AN/AN/AN/ALMATLeMaitre Vascular$0.800.93%+13.30%41.24%14 YearsSIBNSI-BONEN/AN/AN/AN/AN/ALatest SIBN, LIVN, LMAT, and ENOV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/18/2025LMATLeMaitre Vascularquarterly$0.200.9%3/13/20253/13/20253/27/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENOVEnovis0.402.271.12LIVNLivaNova0.463.372.87LMATLeMaitre VascularN/A7.745.52SIBNSI-BONE0.228.257.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENOVEnovis98.45%LIVNLivaNova97.64%LMATLeMaitre Vascular84.64%SIBNSI-BONE98.11%Insider OwnershipCompanyInsider OwnershipENOVEnovis2.40%LIVNLivaNova0.27%LMATLeMaitre Vascular10.79%SIBNSI-BONE3.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENOVEnovis6,80056.96 million55.49 millionOptionableLIVNLivaNova2,90054.35 million54.15 millionOptionableLMATLeMaitre Vascular49022.56 million20.06 millionOptionableSIBNSI-BONE35042.45 million40.30 millionOptionableSIBN, LIVN, LMAT, and ENOV HeadlinesRecent News About These CompaniesSI-BONE (NASDAQ:SIBN) Shares Gap Up - What's Next?April 17 at 10:41 AM | marketbeat.comSI-BONE (NASDAQ:SIBN) Shares Down 4.5% - Time to Sell?April 16 at 12:56 PM | marketbeat.comTrexquant Investment LP Invests $1.23 Million in SI-BONE, Inc. (NASDAQ:SIBN)April 13, 2025 | marketbeat.comWellington Management Group LLP Lowers Position in SI-BONE, Inc. (NASDAQ:SIBN)April 13, 2025 | marketbeat.comSI-Bone price target lowered to $20 from $22 at TruistApril 12, 2025 | markets.businessinsider.comSI-BONE’s Sales Accelerated in final 2024 QuarterApril 11, 2025 | ryortho.comSI-BONE, Inc.: Small-cap Developer Of Medical Implants And A Steady Revenue GrowerApril 8, 2025 | seekingalpha.comSI-BONE, Inc. (NASDAQ:SIBN) Insider Sells $46,850.65 in StockApril 8, 2025 | americanbankingnews.comSI-BONE, Inc. (NASDAQ:SIBN) SVP Sells $44,229.92 in StockApril 6, 2025 | insidertrades.comSI-BONE, Inc. (NASDAQ:SIBN) SVP Michael A. Pisetsky Sells 3,128 SharesApril 6, 2025 | marketbeat.comInsider Selling: SI-BONE, Inc. (NASDAQ:SIBN) Insider Sells 3,311 Shares of StockApril 6, 2025 | marketbeat.comRaymond James Financial Inc. Buys New Shares in SI-BONE, Inc. (NASDAQ:SIBN)April 4, 2025 | marketbeat.comShort Interest in SI-BONE, Inc. (NASDAQ:SIBN) Rises By 40.5%March 31, 2025 | marketbeat.comAmerican Century Companies Inc. Raises Stock Position in SI-BONE, Inc. (NASDAQ:SIBN)March 30, 2025 | marketbeat.comSI-BONE (NASDAQ:SIBN) Shares Gap Up - Here's What HappenedMarch 26, 2025 | marketbeat.comShort Interest in SI-BONE, Inc. (NASDAQ:SIBN) Expands By 17.8%March 20, 2025 | marketbeat.comTocqueville Asset Management L.P. Purchases Shares of 170,000 SI-BONE, Inc. (NASDAQ:SIBN)March 19, 2025 | marketbeat.comHow SI-BONE, Inc. (NASDAQ:SIBN) Continues to Perform Despite Fluctuating Market SupportMarch 8, 2025 | kalkinemedia.comSI-BONE, Inc. 2024 Q4 - Results - Earnings Call PresentationMarch 4, 2025 | seekingalpha.comQ4 2024 SI-BONE Inc Earnings CallFebruary 26, 2025 | uk.finance.yahoo.comBank of America Securities Reaffirms Their Buy Rating on SI-Bone (SIBN)February 25, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSIBN, LIVN, LMAT, and ENOV Company DescriptionsEnovis NYSE:ENOV$31.91 +0.75 (+2.41%) Closing price 04/17/2025 03:59 PM EasternExtended Trading$31.95 +0.04 (+0.12%) As of 04/17/2025 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.LivaNova NASDAQ:LIVN$35.58 +0.51 (+1.45%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$35.58 0.00 (-0.01%) As of 04/17/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.LeMaitre Vascular NASDAQ:LMAT$86.28 +1.61 (+1.90%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$86.28 0.00 (0.00%) As of 04/17/2025 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.SI-BONE NASDAQ:SIBN$13.85 +0.52 (+3.90%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$13.85 0.00 (0.00%) As of 04/17/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation Unveils NYC Network Ahead of Key Earnings Report Joby Aviation Stock Presents an Opportunity in the Turbulence Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Tariff-Resistant Kinder Morgan Is a Good Buy in 2025 Rocket Lab's Growth Potential Gains Altitude on Defense News Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks Tariff-Resistant Abbott Laboratories on Track for New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
